Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 3;13:11211–11220. doi: 10.2147/OTT.S267937

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

miR-455-3p targets BTG2 in OSCC cells. (A) Bioinformatics analysis based on the TargetScan and Starbase database was performed to screen the targets of miR-455-3p. Enrichment analysis of these 279 potential target genes was performed using Metaspace software. (B) The binding site between miR-455-3p and BTG2 was showed. (C) Luciferase assay was carried out to verify the combination of miR-455-3p and BTG2. (D) qPCR was used to assess the BTG2 expression in each group. (E) RNA pulled down experiments was performed to confirm the interaction between miR-455-3p and BTG2. (F) qPCR was used to assess the expression level BTG2 in OSCC tissues. (G) Pearson analysis was performed to evaluate the correlation between miR-455-3p and BTG2 expression level. *P<0.05, **P<0.01, ^##P<0.01.